ATE135043T1 - Gentechnische detoxifikation des pertussistoxins - Google Patents

Gentechnische detoxifikation des pertussistoxins

Info

Publication number
ATE135043T1
ATE135043T1 AT88311133T AT88311133T ATE135043T1 AT E135043 T1 ATE135043 T1 AT E135043T1 AT 88311133 T AT88311133 T AT 88311133T AT 88311133 T AT88311133 T AT 88311133T AT E135043 T1 ATE135043 T1 AT E135043T1
Authority
AT
Austria
Prior art keywords
pertussis
toxin
mutant
vaccine
immunogenic
Prior art date
Application number
AT88311133T
Other languages
English (en)
Inventor
Michel Henri Klein
Heather Anne Boux
Stephen Anthony Cockle
Sheena May Loosmore
Gavin Ross Zealey
Original Assignee
Connaught Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10627453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE135043(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Connaught Lab filed Critical Connaught Lab
Application granted granted Critical
Publication of ATE135043T1 publication Critical patent/ATE135043T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT88311133T 1987-11-24 1988-11-24 Gentechnische detoxifikation des pertussistoxins ATE135043T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878727489A GB8727489D0 (en) 1987-11-24 1987-11-24 Detoxification of pertussis toxin

Publications (1)

Publication Number Publication Date
ATE135043T1 true ATE135043T1 (de) 1996-03-15

Family

ID=10627453

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88311133T ATE135043T1 (de) 1987-11-24 1988-11-24 Gentechnische detoxifikation des pertussistoxins

Country Status (9)

Country Link
US (1) US5085862A (de)
EP (2) EP0688868A1 (de)
JP (1) JP2714068B2 (de)
AT (1) ATE135043T1 (de)
CA (1) CA1341591C (de)
DE (1) DE3855072T3 (de)
ES (1) ES2088778T5 (de)
GB (1) GB8727489D0 (de)
GR (1) GR3019238T3 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0168039B1 (ko) * 1987-09-04 1999-01-15 로버트 디. 웨스트 재조합 dna에서 유도한 보르데텔라 외독소 소단위체의 유사체 및 그를 포함하는 백신
US5925546A (en) * 1987-11-02 1999-07-20 Chiron S.P.A. Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
US6713072B1 (en) * 1987-11-02 2004-03-30 Chiron S.R.L. Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
IT1223334B (it) * 1987-11-02 1990-09-19 Sclavo Spa Polipeptidi immunologicamente attivi con una tossicita' alterata utili per la preparazione di un vaccino antipertosse
US5332583A (en) * 1987-11-24 1994-07-26 Connaught Laboratories Limited Vaccine containing genetically-detoxified pertussis holotoxin
AP8900132A0 (en) * 1988-07-22 1991-01-14 Smithkline Biolog Bordetella pertussis vaccine
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
EP0397834B1 (de) * 1988-10-28 2000-02-02 Genentech, Inc. Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten
US7232671B2 (en) 1989-02-15 2007-06-19 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Pertussis toxin gene: cloning and expression of protective antigen
ATE127347T1 (de) * 1989-04-28 1995-09-15 Sclavo Spa Pertussistoxin-mutanten, dieselbe produzierende bordetella-stämme und ihre verwendung als vakzin gegen pertussis.
ATE143692T1 (de) * 1989-11-29 1996-10-15 Smithkline Beecham Biolog Neuer impfstoff
US5786189A (en) * 1989-11-29 1998-07-28 Smithkline Beecham Biologicals (S.A.) Vaccine
US6197548B1 (en) 1990-04-02 2001-03-06 Medeva Pharma Limited Transformed Pichia expressing the pertactin antigen
US5643753A (en) 1990-04-18 1997-07-01 Connaught Laboratories Limited Use of autologous promoters to express gene products in bordetella
GB9008746D0 (en) * 1990-04-18 1990-06-13 Connaught Lab The use of autologous promoters to express gene products in bordetella
US5637303A (en) * 1990-10-25 1997-06-10 Commonwealth Scientific And Industrial Research Organisation Use of a phospholipase D mutant of Corynebacterium pseudotuberculosis for vaccination
IL101692A0 (en) * 1991-05-03 1992-12-30 Amgen Inc Recombinant b oligomer of pertussis toxin
GB9115332D0 (en) * 1991-07-16 1991-08-28 Connaught Lab Manipulation of gene copy number in bordetella
AU685047B2 (en) * 1992-02-11 1998-01-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
US5856122A (en) * 1993-08-24 1999-01-05 University Of Alberta Modification of pertussis toxin
WO1995009649A1 (en) * 1993-10-05 1995-04-13 Medeva Holdings B.V. Vaccine compositions
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20030072774A1 (en) 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
PT1393744E (pt) 1995-05-04 2011-05-03 Sanofi Pasteur Ltd Vacinas acelulares contra a tosse convulsa e m?todos para a sua prepara??o
EP0912726A4 (de) * 1996-05-10 2001-07-18 Phylomed Corp Verfahren zur oxidation von disulfid-bindungen durch gebrauch von ozon
CA2259415A1 (en) 1996-07-02 1998-01-08 Connaught Laboratories Limited Multivalent dtp-polio vaccines
FR2754543B1 (fr) * 1996-10-11 1998-12-31 Pasteur Institut Souche de bordetella deficiente dans la production de toxine et exprimant une proteine hydride, liposomes comprenant de la fha et leurs utilisations comme vaccins, et utilisation de la fha pour stimuler les reponses immunitaires
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
EP1024826B1 (de) 1997-10-20 2005-03-16 Acambis, Inc. Passive immunisierung gegen durch clostridium difficile verursachte krankheit
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
DK1296715T4 (en) 2000-06-29 2016-03-07 Smithkline Beecham Biolog Multivalent vaccine composition.
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
US7556807B2 (en) 2001-02-20 2009-07-07 Kane Biotech, Inc. Signal peptides, nucleic acid molecules and methods for treatment of caries
US7597895B2 (en) * 2001-02-20 2009-10-06 The Governing Council Of The University Of Toronto Signal peptides, nucleic acid molecules and methods for treatment of caries
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
AU2004292547B9 (en) * 2003-11-20 2012-04-26 Sanofi Pasteur, Inc. Methods for purifying pertussis toxin and peptides useful therefor
EP2857418B1 (de) 2004-02-06 2017-07-26 University of Massachusetts Antikörper gegen Clostridium difficile Toxine und ihre Verwendung
EP1774017B1 (de) 2004-07-26 2013-05-15 Pfenex Inc. Verfahren zur verbesserten proteinexpression durch strain-engineering
US9394571B2 (en) 2007-04-27 2016-07-19 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
AR077636A1 (es) 2009-07-08 2011-09-14 Abbott Biologicals Bv Vacuna viral y uso de la misma
EP2553102B1 (de) 2010-03-30 2015-12-09 Pfenex Inc. Hochleistungs-expression rekombinanter toxinproteine
WO2012118693A1 (en) 2011-02-28 2012-09-07 Northshore University Healthsystem Methods of diagnosing clostridium difficile infection
BR112014004162A2 (pt) 2011-08-22 2018-04-24 Cangene Corp anticorpos contra clostridium difficile
IN2014CN04700A (de) 2011-12-21 2015-09-18 Bionet Asia Co Ltd
NZ714516A (en) 2012-03-02 2017-06-30 Regeneron Pharma Human antibodies to clostridium difficile toxins
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
SG11201500573RA (en) 2012-08-06 2015-02-27 Glaxosmithkline Biolog Sa Method for eliciting in infants an immune response against rsv and b. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
CA2886938A1 (en) * 2012-10-12 2014-04-17 Glaxosmithkline Biologicals S.A. Non-cross-linked acellular pertussis antigens for use in combination vaccines
US10117933B2 (en) 2012-11-28 2018-11-06 Emergent Biosolutions Canada Inc. Antibodies against Clostridium difficile
ES2843509T3 (es) 2013-01-04 2021-07-19 Obi Pharma Inc Vacunas con mayor densidad de antígeno carbohidratado y nuevo adyuvante de saponina
CN105007936B (zh) 2013-03-08 2018-10-02 扬森疫苗与预防公司 无细胞百日咳疫苗
AU2014304545A1 (en) 2013-08-05 2016-02-25 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340373C (en) * 1986-01-28 1999-02-02 Rino Rappuoli Cloning and sequencing of the dna fragment which codes for the five subunits of the pertussis toxin, a hybrid plasmid containing the dna fragment and micro-organisms transformed by the hybrid plasmid and capable of expressing all or some of the subunits of the pertussis toxin
DE3781541T2 (de) * 1986-12-23 1993-05-06 Univ Leland Stanford Junior Modifiziertes pertussistoxin.
KR0168039B1 (ko) * 1987-09-04 1999-01-15 로버트 디. 웨스트 재조합 dna에서 유도한 보르데텔라 외독소 소단위체의 유사체 및 그를 포함하는 백신
IT1223334B (it) * 1987-11-02 1990-09-19 Sclavo Spa Polipeptidi immunologicamente attivi con una tossicita' alterata utili per la preparazione di un vaccino antipertosse
AP8900132A0 (en) * 1988-07-22 1991-01-14 Smithkline Biolog Bordetella pertussis vaccine

Also Published As

Publication number Publication date
DE3855072T3 (de) 2001-08-02
GR3019238T3 (en) 1996-06-30
ES2088778T5 (es) 2001-09-01
EP0322115B2 (de) 2001-02-28
JPH022383A (ja) 1990-01-08
EP0322115B1 (de) 1996-03-06
DE3855072T2 (de) 1996-11-14
CA1341591C (en) 2009-02-17
EP0322115A3 (en) 1989-08-23
JP2714068B2 (ja) 1998-02-16
EP0688868A1 (de) 1995-12-27
EP0322115A2 (de) 1989-06-28
DE3855072D1 (de) 1996-04-11
ES2088778T3 (es) 1996-09-16
US5085862A (en) 1992-02-04
GB8727489D0 (en) 1987-12-23

Similar Documents

Publication Publication Date Title
DE3855072D1 (de) Gentechnische Detoxifikation des Pertussistoxins
Turnbull Anthrax vaccines: past, present and future
Khelef et al. Bordetella pertussis and Bordetella parapertussis: two immunologically distinct species
DE69333028D1 (de) Deletionsmutanten als impfstoffe gegen cholera
GR3017497T3 (en) Recombinant DNA-derived bordetella toxin subunit analogs.
AU5394699A (en) Molecular differences between species of the (m. tuberculosis) complex
NO1997010I1 (no) Bordetella pertussis P69 antigen
GR970300034T1 (en) Vaccine containing Bordetella pertussis outer membrane protein, and method of making such vaccine
EP1184459A2 (de) Manipulierung der Anzahl von Genkopien bei Bordetella
DK0892054T3 (da) Clostridium perfringens-vaccine
Rappuli et al. Progress towards the development of new vaccines against whooping cough
Podda et al. Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine
ATE107516T1 (de) Pasteurella-impfstoff.
EP0352250B1 (de) Impfstoff gegen Bordetella pertussis
Rappuoli et al. Recombinant acellular pertussis vaccine—from the laboratory to the clinic: improving the quality of the immune response
KR920703098A (ko) 신규 백신
Klein et al. Genetic detoxification of pertussis toxin
Klein et al. Immunoprotective genetically-detoxified mutants of pertussis toxin
Miller Acellular pertussis vaccines
BURNETTE et al. Pertussis Toxin SI Mutant with Reduced Enzyme Activity and a Conserved Protective Epitope
MacGregor et al. Serotype variation in Bordetella pertussis is governed by cis-acting elements
Wright Genetic manipulation of type D Pasteurella multocida for vaccine development
HK1004568B (en) Bordetella pertussis vaccine
MX9708480A (es) Vacunas acelulares de pertussis y metodos de preparacion de las mismas.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification
EEFA Change of the company name
EELA Cancelled due to lapse of time